• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?

0
  • by alexperjescuadmin
  • in Oncology
  • — 27 Apr, 2009
Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?
John S. Macdonald MD FACP
Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?
AudioMedica News
Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?
Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?
00:00 /
RSS Feed
Share
Link
Embed
John S. Macdonald MD FACP

John S. Macdonald MD FACP

11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles about his data on the relevance of KRAS tumor status to the choice of molecular therapy for patients with metastatic colorectal cancer. Whether the gene is wild-type or mutant determines sensitivity of the tumor to anti-epidermal growth factor or anti-vascular endothelial growth factor receptor therapy. Dr Macdonald also discusses the disappointing finding that blocking both of these proliferation pathways does not lead to improved efficacy when two targeted drugs are used in combination.


LISTEN

[audio:https://www.audiomedica.com/podcasting/otbn/090426JohnMacdonaldOTBN.mp3]

Share

You may also like...

  • ASCO Annual Meeting Daily News Podcasts – June 5th, 2007 ASCO Annual Meeting Daily News Podcasts – June 5th, 2007 5 Jun, 2007
  • ASCO Audio Journal of Oncology in Advance – July 15th, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007 ASCO Audio Journal of Oncology in Advance – July 15th, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007 15 Jul, 2007
  • Tumour heterogeneity — clonal evolution of cancer limits effectiveness of targeted systemic therapies Tumour heterogeneity — clonal evolution of cancer limits effectiveness of targeted systemic therapies 26 Mar, 2014
  • Chronic Lymphocytic Leukemia After Fludarabine Failure Chronic Lymphocytic Leukemia After Fludarabine Failure 26 Feb, 2008

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Chronic Myeloid Leukemia ‘To Become A Very Indolent Disease’: Pregnancy Possible, Transplants Avoided—Mission Accomplished?
  • Next story H1N1 Influenza Pandemic: How Good Are Existing Preparations?
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Which New Combination for Metastatic Renal Cell Cancer?
    • Microbiome Diversity Key To Survival After…
    • New Front Line Standard for Older Patients with…
    • Genomic-led AML Clinical Decision Making Within Seven Days
  • Home
  • Oncology
  • Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.